CNDO Share Price

Open 3.97 Change Price %
High 4.03 1 Day -0.53 -13.35
Low 3.40 1 Week 0.00 0.00
Close 3.44 1 Month 0.00 0.00
Volume 893290 1 Year 0.00 0.00
52 Week High 61.65
52 Week Low 38.26
CNDO Important Levels
Resistance 2 4.02
Resistance 1 3.78
Pivot 3.62
Support 1 3.10
Support 2 2.86
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Coronado Biosciences, Inc. (NASDAQ: CNDO)

CNDO Technical Analysis 3
As on 27th Apr 2015 CNDO Share Price closed @ 3.44 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.25 & Buy for SHORT-TERM with Stoploss of 3.32 we also expect STOCK to react on Following IMPORTANT LEVELS.
CNDO Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CNDO Other Details
Segment EQ
Market Capital 124316320.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.coronadobiosciences.com
CNDO Address
CNDO
24 New England Executive Park
Suite 105
Burlington, MA 01803
United States
Phone: 781-652-4500
Fax: 781-652-4545
Interactive Technical Analysis Chart Coronado Biosciences, Inc. ( CNDO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Coronado Biosciences, Inc.
CNDO Business Profile
Coronado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company�s two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn�s disease (Crohn�s), ulcerative colitis (UC) and multiple sclerosis (MS), and CNDO-109, a compound that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells, for the treatment of acute myeloid leukemia (AML). In January 2011, the Company acquired the OvaMed GmbH License.